Skip to main content
. Author manuscript; available in PMC: 2010 Jul 7.
Published in final edited form as: Oncogene. 2009 Oct 5;29(1):34–44. doi: 10.1038/onc.2009.305

Figure 6. ROR2 decreases motility and invasiveness in metastatic in human melanoma cell lines in vitro and in vivo.

Figure 6

Using a Matrigel invasion assay, ROR2 knockdown inhibits the invasion of UACC903 and M93-047 cells by over 50% (A). Two different siRNAs were used to demonstrate the requirement for ROR2, see also Supplementary Figure 3. G361 cells are similarly affected in a matrigel invasion assay, where Wnt5A treatment can significantly (**=p<0.01, ***=p<0.001) increase their migration through Matrigel, but not in the presence of ROR2 siRNA (B). When M93-047 29 cells are injected via the tail vein into nude mice, ROR2 knockdown results in a decreased ability of M93-047 cells to form pulmonary metastases (C). Two lungs with evidence of macroscopic metastases are shown and a histology section from a third mouse (C, arrow) is shown in order to demonstrate the hemorrhaging seen in these tumors.